Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Pentoxifylline for the treatment of severe alcoholic hepatitis

A study published ahead of print in the Alimentary Pharmacology & Therapeutics evaluates pentoxifylline for the treatment of severe alcoholic hepatitis.

News image

Acute alcoholic hepatitis is a severe manifestation of alcoholic liver disease with a grave prognosis.

Pentoxifylline, an oral antitumor necrosis factor agent, has been reported to reduce mortality and incidence of hepatorenal syndrome in severe alcoholic hepatitis.

Dr Parker and colleagues summarized evidence for the use of pentoxifylline in severe alcoholic hepatitis.

The team performd a literature search was undertaken using MeSH terms ‘hepatitis, alcoholic’ and ‘pentoxifylline’ using the set operator AND.

The research team included randomized controlled trials examining pentoxifylline in severe alcoholic hepatitis, published as abstracts or full manuscripts.

Risk ratios were calculated for pooled data using random effects modelling.

The team of doctors examined that the risk of bias was assessed using Cochrane group criteria and quality of trials assessed using ‘Consolidated Standards of Reporting Trials’ CONSORT guidelines.

The team included 10 trials with 884 participants, from 6 papers and 4 abstracts.

There was a reduced incidence of fatal hepatorenal syndrome with pentoxifylline
Alimentary Pharmacology & Therapeutics

The research team noted that there was significant heterogeneity between trials regarding control groups and trial end-points.

Treatment was given for 28 days in all trials except one.

The doctors examined that the pooling of data showed a reduced incidence of fatal  hepatorenal syndrome with pentoxifylline compared with placebo, but no survival benefit at 1 month.

There were no significant differences between treatment groups in trials of pentoxifylline vs. corticosteroid, or vs. combination therapy.

Dr Parker's team commented, "Pentoxifylline appears superior to placebo in prevention of fatal hepatorenal syndrome and thus may be effective treatment of severe alcoholic hepatitis when corticosteroids are contraindicated."

"However, multiple trials have failed to show conclusive superiority of either pentoxifylline or corticosteroids."

Aliment Pharmacol Ther 2013
29 March 2013

Go to top of page Email this page Email this page to a colleague

 26 August 2016 
Bleeding after endoscopic dissection-induced gastric ulcers
 26 August 2016 
Reasons for premature surveillance colonoscopy
 26 August 2016 
Celiac disease therapeutics
 25 August 2016 
Post-infectious IBS in C. diff
 25 August 2016 
Stool DNA test for colorectal cancer screening
 25 August 2016 
Short-chain fatty acids in mixed refractory constipation
 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Hep B after infant vaccination program
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us